Sarepta Therapeutics Announces FDA Approval To Submit NDA For Eteplirsen
May 19, 2015 at 19:05 PM EDT
Shares of Sarepta Therapeutics are up 38% following news that the FDA will allow the company to submit an NDA for Eteplirsen approval.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.